Drug Discovery World

OCTOBER 5, 2023

The presentations will be followed by a panel discussion addressing new drug discovery and development concepts and tools in cancer research, and how these new approaches – e.g. engineered proteins, antibodies, micro RNA, nanocarriers, antibody drug conjugates – can help address unmet need in oncology. More to be announced.

Research 52

Research Antibody Medicine RNA 52

Drug Discovery World

DECEMBER 21, 2023

Other biotechnologies coming to the fore this year were antibody-drug conjugates and CRISPR gene editing. Three trends in the antibody-drug conjugate (ADC) market Antibody-drug conjugates are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker.

Gene Therapy 59

Gene Therapy Gene Antibody FDA Approval 59

Drug Discovery World

MAY 13, 2024

Key to this is the ability to rapidly determine protein structures alone and in combination with antibodies or small molecules. This allows researchers to quickly view, for example, how many different antibodies are binding to a vaccine or virus. RA: How reliable are vaccines now for respiratory viruses such as flu?

Vaccination 59

Vaccination Vaccine Protein Antibody 59

Pharmaceutical Technology

DECEMBER 9, 2022

In regards to the latter, notable examples include the acquisition of Cergentis, a genomics-focused biotechnology company based in the Netherlands. The deal allows the company to provide proprietary technology and knowledge steeped in fast-evolving genomic techniques that support effective decision-making and R&D program design.

Development 130

Development Manufacturing Production Vaccination 130

Drug Discovery World

MARCH 13, 2024

In 2019 he was part of a research team which discovered humanised antibody, PRL3-zumab, was effective at shrinking PRL3 over-expressing tumours, and which has since been approved for Phase II clinical trials in Singapore, the US and China. There has also been significant investment in infrastructure in the country.

Life Science 69

Life Science Genome Genomics Research 69

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.

Drugs 76

Drugs Life Science Gene Therapy Genome 76

XTalks

NOVEMBER 30, 2023

Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable. The noteworthy candidate, EBT-101, is designed to eliminate HIV proviral DNA using CRISPR-Cas9 along with two guide RNAs (gRNAs).

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccination Vaccine Development 40

pharmaphorum

SEPTEMBER 22, 2022

When exposed to a virus, one’s immune system develops antibodies in response to foreign antigens, with or without a vaccine. One arm of the immune system triggers antibodies, and the other triggers T-cells. Antibodies cover the pathogen of the virus and neutralise it. “On this front, the antibody works very well.

Vaccination 96

Vaccination Vaccine Antibody Clinical Trials 96

pharmaphorum

JANUARY 20, 2021

A genomic analysis of the SARS-CoV-2 coronavirus, which causes COVID-19, shows that the virus accumulates around two mutations a month. The variant that originated in South Africa carries a mutation in the Spike protein that has been shown to reduce antibody recognition and could therefore affect efficacy of new vaccines.

Vaccination 52

Vaccination Vaccine Protein RNA 52

Drug Discovery World

APRIL 6, 2023

from Fabien Vincent, Pfizer, Groton, US High content phenotypic and pathway profiling identifies novel drug mechanisms-of-action tailored towards cancers of unmet need by Neil Carragher, University of Edinburgh, Edinburgh, UK Functional genomics as an enabling tool for phenotypic screening by Matthew Garnett Chemistry to the Clinic: Part 1-3: (..)

Protein 52

Protein Clinical Trials Clinical Trials Antibody 52

XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs. Detection of Genomic Alterations from cfDNA: Targeted, Non-Personalized Approaches.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

Big Data 40

Big Data Development Life Science Drugs 40

The Pharma Data

DECEMBER 10, 2020

The goal of targeting both S and N was to both activate virus-specific T cells and generate anti-SARS-CoV-2-neutralizing antibodies. ImmunityBio’s hAd5 vaccine generated robust neutralizing antibody activity that was present 14 days post-final vaccination. This press release features multimedia. Graphic: Business Wire).

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. They compared these sequences with the original SARS-CoV-2 genome, cross-checking the genetic changes against their highly networked epitopes. 1.351 Beta, P1 Gamma, and B.1.617.2

Vaccination 52

Vaccination Vaccine Research Immune Response 52

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. CRISPR diagnostics have successfully detected various pathogens, including RNA viruses (eg. parvovirus B19, Flaviviridae, Ebola, and Coronaviridae), DNA viruses (e.g.,

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

AUGUST 10, 2022

Next, the advent of antibody treatments in 1997 created the first targeted cancer therapy 2. Later, scientists took advantage of antibodies’ natural tendency to seek out specific antigens and created antibody therapies that guide T cells towards the cells they are supposed to destroy.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

The Pharma Data

DECEMBER 3, 2020

For example, “Viral antigens and antibodies (typically IgM and IgG) become detectable at different periods during infection…and the detection time…depends on several parameters, such as viral features, individual patient variability and the applied test.” Advantages include sensitivity, better limit of detection, and miniaturization.

RNA 52

RNA Protein DNA Antibody 52

Drug Discovery World

NOVEMBER 15, 2022

Applications: The ability to synthesise longer, accurate DNA sequences opens up a vast array of application possibilities: generating CRISPR libraries, in situ hybridisation probes, antibody libraries, vaccines, and so on, along with the ability to engineer metabolic pathways, microbes, and plants. .

DNA 98

DNA Drugs Antibody Engineer 98

XTalks

OCTOBER 26, 2023

The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA. Both influenza and SARS-CoV-2 have RNA as their genetic material. An RNA genome enables the genetic material to mutate more rapidly. For COVID, it is much the same case.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

Drug Discovery World

SEPTEMBER 6, 2022

However, whilst these comments largely reflect a positive outlook for investment in the industry, financing in Q1 of 2022 largely remained level with the backend of last year, hovering just over $500 million according to American Society of Gene & Cell Therapy’s (ASGCT) – Gene, Cell, & RNA Therapy Landscape Q1 report. .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

The Pharma Data

MARCH 20, 2021

Coronaviruses are RNA viruses and include common human coronaviruses, severe acute respiratory syndrome-CoV (SARS-CoV), Middle East respiratory syndrome-CoV (MERS-CoV) and SARS-CoV-2 ( 1 ). Detection of virus-specific antibodies allows for diagnosis of recent symptomatic or even asymptomatic infections. INTRODUCTION.

Protein 52

Protein Antibody Development RNA 52

Drug Discovery World

FEBRUARY 6, 2023

This approach has led to the development of two software packages for RNA sequencing analysis and reproducible ribosomal profiling 1,2. For example, we recently collaborated with two sequencing laboratories to determine optimal parameters for RNA-Sequencing (RNA-Seq) in the context of a vaccine clinical trial.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. At PhoreMost, we have been particularly excited about the emergence of targeted protein degradation (TPD) as a new therapeutic modality.

Research 52

Research Drugs Protein RNA 52

pharmaphorum

JULY 13, 2022

The first subject has now been given a dose of VERVE-101, in what is thought to be the first test in humans of an experimental CRISPR/Cas9 genome editing technique known as base editing. Through base editing, drugs replace single nucleotide in the DNA strand with another, without making double-strand breaks (DSBs) in the gene.

Gene Editing 98

Gene Editing Trials Drugs Gene 98

The Pharma Data

APRIL 30, 2021

a leading clinical-stage CRISPR genome editing biotechnology company, announced that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. AbbVie and Caribou Biosciences, Inc.,

Botox 40

Botox Production Development Cosmetics 40

Drug Discovery World

JUNE 6, 2023

Jordan also commented on a resurgence in antibody drug conjugates (ADCs), noting the higher drug loading, better payload stability, better tissue penetrance, and thinks that will continue. From that, we’ll understand better how to use targeted therapies.” It’s a 1.5 It’s really all driven by the Archer technology.

Protein 52

Protein DNA RNA Research 52

XTalks

DECEMBER 24, 2020

From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. Most antibody drugs and vaccines have been developed to target parts of the spike protein. Drug Approvals.

Life Science 111

Life Science Vaccination Vaccine Gene 111

The Pharma Data

JANUARY 7, 2021

” Armstrong told the Post that the CDC hopes to more than double the number of genomic sequences of the virus posted on public websites within the next two weeks. ” In addition to the herd immunity issue, any variants could limit the power of antibody treatments because those treatments are so narrowly focused.

Vaccination 52

Vaccination Vaccine Antibody RNA 52

Pfizer

NOVEMBER 2, 2022

The first participant has been dosed in a Phase 1 trial evaluating the safety, tolerability, and immunogenicity of a nucleoside-modified RNA (modRNA)-based combination vaccine approach. 5) vaccine, each of which is based on BioNTech’s proprietary mRNA platform technology. .

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

Pharmaceutical Technology

APRIL 27, 2023

Genomic medicine development was ranked as the top industry trend for 2023 in a survey of 198 GlobalData Pharma clients and prospects conducted between October and November 2022. GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6 billion by 2028. billion by 2028.

Manufacturing 130

Manufacturing RNA Contamination Vaccination 130